SNDX · Syndax Pharmaceuticals Inc
United States · RS rating 22 · As of 2026-11-03
| Price | 14.29 USD |
|---|---|
| 1-day change | +9.1% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 22 / 22 / 55 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 5 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -11.4% |
| Sales growth Q/Q | +49.8% |
| Distance from 52-week high | +43.2% |
| Market cap (USD) | $1.9B |